The regulation of CUGBP1-mediated crosstalk between TGF-β and IFN-γ signalling pathways via genetic down-regulation or the treatment with fraxinellone may provide a novel strategy for the therapy of liver fibrosis (Fig. 10). The gene discussed is CELF1; the disease is Hepatic fibrosis.